AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard

Project Information

ABT

Grant agreement ID: 856264

DOI

10.3030/856264

Project closed

EC signature date 31 January 2019

Start date 1 February 2019

End date 31 July 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

ENPROJECT MEDICALI SRL
Italy

Periodic Reporting for period 1 - ABT (AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard)

Reporting period: 2019-02-01 to 2019-07-31

Summary of the context and overall objectives of the project

Biological hazards are organic substances that pose a threat to the health of humans and other living organisms. Biological hazards include pathogenic micro-organisms, viruses, toxins (from biological sources), spores, fungi and bio-active substances. Biological hazards can also be considered to include biological vectors or transmitters of disease. Worldwide, it is estimated that around 320 000 workers die each year from communicable diseases caused by work-related exposures to biological hazards. We have developed ABT 9000 the first medical technology able to completely eliminate the biological risk in medical wards unit and hospital stays at affordable cost and with no environmental impact (after the treatment the biological fluids are turned into water).The overall objective of the project was to determine the viability of ABT 9000 and to carry out the necessary activities to ensure market success. These activities began validating the technological feasibility, identifying its potential features and its limitations and defining a development plan with clear milestones after redefining the product range based on the market inputs. Another objective was to perform a thorough market assessment, quantifying the market size, identifying potentially interested customers and technological partners, defining eventual pilot projects, both of technological implementation and of validation with potential clients, detecting relevant regulations, competitors, market barriers and growth potential. Another relevant objective was to define an IPR strategy and the work plan for Phase 2, assessing possible risks.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

• We have created an ecosystem of partners covering all the actors involved in our value chain and business model: industrial partners (USA STAMPI), final users (hospital of Frosinone, Hospital of Catania, Campus Biomedico, Umberto I Roma), distributors (CEMSA) and private investor (Rerum Novarum). Thanks to this ecosystem, we have been able to perform a thorough market assessment, analyse the competitive landscape, validate the need we are targeting with the users, redefine the specifications of the product to make a realistic minimum viable product, regarding both the functional features and the price, and assess the technological feasibility of its implementation and validation, while having in mind the final ideal solution and the road to achieve it. For that purpose, we have grown the team incorporating agile work methodologies, and experts in different key fields for the company have joined our advisory board. With these resources, we have assessed operational, technological and economic viability, as well as elaborated a robust Business Plan to define the business growth, sustainability, exploitation strategies, and tactics to pave the way to a global market.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Hospitals and other healthcare facilities are responsible for the delivery of patient care services and during this process, certain amount of waste is generated in the form of swabs, discarded syringes and plastics, unused specimens etc., which are collectively known as biomedical waste. Among the biomedical waste, the biological fluids is extremely dangerous because it is highly infectious and it can affects the health of the medical staff operators. For that reasons standardized treatment procedures outlines chemically treatments in order to mitigate the biological risks. However current technologies offer only a partial solutions because are not able to degrade completely the biological fluids (100% RNases), are expensive and, often, does not permit a treatment on site. ABT innovation mainly lies in the use of Adantium® Plus and Axivirium BIOACTIVE® molecules that enable the neutralization of biological liquids with high degree of infectivity in one minute. We clearly differentiate ourselves with a truly innovative product that meets a real market demand by our unique selling points (USPs) that includes:
Eliminate the biological risk in TIPO cardiological unit and hospital stays.
Zero environmental impact: after the treatment the biological fluids are turned into water.
Complete traceability of the biological fluids treated.
Competitive price.
Strong IP protection.

ABT 9000